Peptide Therapeutics Market Size to Hit USD 91.25 Bn by 2031 | TMR Study


Global peptide therapeutics market growth is driven by the high incidence, prevalence of metabolic disorders and the growth in the geriatric population across the globe. North America is projected to dominate the global market for peptide therapeutics during the forecast period.

Wilmington, Delaware, United States, April 15, 2023 (GLOBE NEWSWIRE) — The worldwide market for peptide therapeutics is forecasted to augment at a CAGR of 8.8% from 2022 to 2031. According to Transparency Market Research, sales of Peptide Therapeutics are slated to total USD 91.25 Bn by the end of the aforementioned period of assessment.

The peptide therapeutics market is expected to continue growing in the coming years, driven by the advancements in peptide synthesis and manufacturing technologies and the growing demand for targeted therapies and personalized medicine are expected to drive the market growth.


Download a Sample for Highlights on Market Drivers and Challenges Affecting the Peptide Therapeutics:

Market Snapshot:

Report Coverage  Details
Market Revenue  USD 39.34 Bn in 2021
Estimated Value  USD 91.25 Bn by 2031
Growth Rate  8.8%  
Forecast Period  2022–2031
No. of Pages  211 Pages
Market Segmentation  By Application, Route of Administration, Type, Technology, Type of Molecule, and API Peptide Type
Regions Covered  North America, Europe, Asia Pacific, Middle East & Africa, South America
Companies Covered  Amgen, Inc., Bachem Holding AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

However, challenges such as the high cost of development and manufacturing of peptide-based drugs and limited availability of healthcare infrastructure in certain regions need to be addressed. Overall, the peptide therapeutics market presents significant opportunities for growth and innovation in the coming years.

Key Findings of the Market Report

  • Cancer is the largest therapeutic area for peptide therapeutics, followed by metabolic, CVD, and anti-Infective segments
  • Over the past decade, there has been a significant increase in the number of FDA-approved peptide drugs, with over 60 peptides approved for use in the US market.
  • With the growing demand for personalized medicine, there is an increasing focus on developing peptide-based therapeutics that target specific genetic mutations or biomarkers.

Peptide Therapeutics Market Growth Drivers & Trends

  • Advances in peptide synthesis and manufacturing technologies have led to the development of more efficient and cost-effective methods of producing peptides, leading to a surge in research and development activities in the field of peptide therapeutics.
  • Targeted therapies, such as peptide-based therapeutics, are becoming increasingly popular due to their ability to selectively target disease-causing cells or proteins, leading to improved treatment outcomes and reduced side effects.
  • With the growing demand for personalized medicine, there is an increasing focus on developing peptide-based therapeutics that target specific genetic mutations or biomarkers, leading to improved treatment outcomes and reduced side effects.
  • Over the past decade, there has been a significant increase in the number of FDA-approved peptide drugs, leading to increased awareness and adoption of peptide-based therapeutics.
  • Long-acting peptide formulations are gaining popularity due to their ability to improve patient compliance and reduce the number of injections needed, leading to improved treatment outcomes.


Global Peptide Therapeutics Market: Regional Profile

  • North America is the largest market for peptide therapeutics, accounting for over 40% of the global market share. The high market share is attributed to the presence of a large number of pharmaceutical companies, high healthcare spending, and favorable government initiatives. The US is the largest contributor to the North American peptide therapeutics market.
  • Europe is the second-largest market for peptide therapeutics, accounting for approximately 25% of the global market share. The market growth is driven by increasing research and development activities, a large patient population, and rising demand for targeted therapies. Germany, France, and the UK are the prominent contributors to the European peptide therapeutics market.
  • The Asia Pacific peptide therapeutics market is expected to grow at the highest CAGR during the forecast period. The market growth is attributed to the increasing prevalence of chronic diseases, rising healthcare expenditure, and growing demand for personalized medicine. China, Japan, and India are the major contributors to the Asia Pacific peptide therapeutics market.

Peptide Therapeutics Market: Competitive Landscape

The peptide therapeutics market is highly competitive, with a large number of players operating in the industry. Here are some of the major companies operating in this space:

  • Amgen, Inc.
  • Bachem Holding AG
  • Eil Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Some key developments with regard to Peptide Therapeutics are as follows:

  • In July 2021, the renowned pharmaceutical giant, Eli Lilly, made a strategic move by acquiring Protomer Technologies, a biotech company with a revolutionary platform for developing peptide-based drugs. With this acquisition, Eli Lilly is set to soar to even greater heights in the world of peptide therapeutics.
  • In May 2021, Novartis announced that it had completed the acquisition of The Medicines Company, a biotech company that is developing novel treatments for cardiovascular diseases. The acquisition is expected to help Novartis strengthen its pipeline of innovative treatments.

Buy this Premium Research Report | Immediate Delivery Available at

Peptide Therapeutics Market: Key Segments

By Application

  • Cancer
  • Metabolic
  • CVD
  • Respiratory
  • GIT
  • Anti-Infective
  • Dermatology
  • CNS
  • Renal

By Route of Administration

  • Parental
  • Oral

By Type

  • Innovative
  • Generic

By Technology

  • Liquid Phase
  • Solid Phase
  • Hybrid Phase

By Type of Molecule

  • Vasopressin
  • Somatostatin
  • Calcitonin
  • Natriuretic

By API Peptide Type

  • In-house
  • CMO

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Nikhil Sawlani
Transparency Market Research Inc.
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.